Glatfelter (NYSE:GLT) reported quarterly losses of $(0.14) per share which missed the analyst consensus estimate of $(0.07) by 100 percent. This is a 173.68 percent decrease over earnings of $0.19 per share from the same period last year.
Roivant, Pfizer Form New Vant Company Focused On Developing TL1A Drug Candidate For Inflammatory And Fibrotic Diseases
Roivant to develop PF-06480605 (now RVT-3101), a potential first in class, fully human monoclonal antibody that blocks tumor necrosis factor-like ligand 1A (TL1A), a cytokine believed to play a key role in inflammation